- Featured Product
- KD/KO Validated
PRAME Monoclonal antibody
PRAME Monoclonal Antibody for WB, IF/ICC, ELISA
Host / Isotype
Mouse / IgG2b
Reactivity
Human, mouse, rat
Applications
WB, IF/ICC, ELISA
Conjugate
Unconjugated
CloneNo.
1E9G9
Cat no : 68097-1-Ig
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | A549 cells, HeLa cells, A375 cells, mouse testis tissue, K-562 cells, U2OS cells |
Positive IF/ICC detected in | HaCaT cells |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:5000-1:50000 |
Immunofluorescence (IF)/ICC | IF/ICC : 1:400-1:1600 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
68097-1-Ig targets PRAME in WB, IF/ICC, ELISA applications and shows reactivity with Human, mouse, rat samples.
Tested Reactivity | Human, mouse, rat |
Host / Isotype | Mouse / IgG2b |
Class | Monoclonal |
Type | Antibody |
Immunogen | PRAME fusion protein Ag1906 相同性解析による交差性が予測される生物種 |
Full Name | preferentially expressed antigen in melanoma |
Calculated molecular weight | 509 aa, 58 kDa |
Observed molecular weight | 50 kDa |
GenBank accession number | BC014074 |
Gene symbol | PRAME |
Gene ID (NCBI) | 23532 |
RRID | AB_2918834 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
The PRAME (preferentially expressed antigen of melanoma) gene was previously shown to be overexpressed in ovarian/primary peritoneal serous carcinoma compared with malignant mesothelioma using gene expression arrays. It is considered a melanocyte differentiation antigen which is overexpressed in both solid and hematologic tumors. In normal tissue, a very low level of PRAME expression is found in normal testis, adrenals, ovary and endometrium. A high level of PRAME expression has been reported for several solid tumors, including ovarian cancer, breast cancer, lung cancer and melanomas, medulloblastoma, sarcomas, head and neck cancers, neuroblastoma, renal cancer, and Wilms'tumor. As a nuclear transcriptional repressor protein, PRAME binds to retinoic acid receptor a, thereby inhibiting retinoic acid induced differentiation, growth arrest, and apoptosis.
Protocols
Product Specific Protocols | |
---|---|
WB protocol for PRAME antibody 68097-1-Ig | Download protocol |
IF protocol for PRAME antibody 68097-1-Ig | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |